
    
      This was a phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to
      evaluate the safety, tolerability and pharmacokinetics of MEDI8897 compared to placebo when
      administered to healthy adult participants. There were 136 participants randomized to receive
      MEDI8897 or placebo at one site. Investigational product was delivered intravenously (IV) to
      3 cohorts and intramuscularly (IM) to 2 cohorts. 4 different dose levels of investigational
      product were evaluated across the 5 cohorts. Participants were followed for approximately 1
      year.
    
  